ETX 810
Alternative Names: ETX-018810; ETX-810Latest Information Update: 04 Aug 2022
At a glance
- Originator Eliem Therapeutics
- Class Analgesics; Lipids; Non-opioid analgesics
- Mechanism of Action Cannabinoid receptor agonists; G-protein-coupled receptor 55 modulators; Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain; Sciatica
Most Recent Events
- 02 Aug 2022 Discontinued - Phase-II for Neuropathic pain (In the elderly, In adults) in USA (unspecified route)
- 02 Aug 2022 Discontinued - Phase-II for Sciatica in USA (PO)
- 28 Jun 2022 Eliem Therapeutics completes a phase IIa trial in Sciatica in USA (PO) (NCT04778592) .